98. Eosinophilic gastrointestinal disease Clinical trials / Disease details

Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02493335 (ClinicalTrials.gov)	January 15, 2016	7/7/2015	Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis	Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis	Eosinophilic Esophagitis	Drug: Budesonide 0.5mg orodispersible tablet twice daily;Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily	Dr. Falk Pharma GmbH	NULL	Completed	18 Years	75 Years	All	204	Phase 3	Germany
2	NCT02434029 (ClinicalTrials.gov)	November 11, 2015	30/4/2015	Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis	Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis	Eosinophilic Esophagitis	Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily	Dr. Falk Pharma GmbH	NULL	Completed	18 Years	75 Years	All	88	Phase 3	Germany